+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 0 - 21Years
All Genders
ID04558736

Haploidentical Hematopoietic Cell Transplantation Using TCR -Depleted Donor Cells for Patients With Severe Aplastic Anemia Without Matched Donors

Led by St. Jude Children's Research Hospital · Updated on 2026-09-16

21

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying a new approach for treating patients with Severe Aplastic Anemia SAA who do not have a fully matched family donor. This phase II clinical trial evaluates the safety and effectiveness of haploidentical hematopoietic cell transplantation HCT, which uses blood-forming cells donated by a family member who is only partially matched. The study aims to learn about the effects of chemotherapy, radiation, the transplanted cells, and additional white blood cell infusions on patient outcomes, including overall survival and event-free survival at one year after transplant. Participants receive chemotherapy, antibodies, and radiation to prepare their bodies for the transplant. They will be given two types of donor cell infusions a special progenitor blood cell infusion TCR -depleted cells followed by a donor lymphocyte infusion CD45RA-depleted lymphocytes after engraftment. These cells are processed using the CliniMACS device to help reduce graft-versus-host disease GVHD, improve immune recovery, and expand donor options by allowing use of haploidentical donors. The goal is to test a combination of GVHD prevention methods to improve transplant safety and immune system rebuilding. Throughout the study, participants will be closely monitored with assessments at multiple time points up to one year post-transplant. Researchers will measure engraftment rates at 30 days, survival outcomes, GVHD occurrence, graft rejection, viral infections, and immune system recovery. Additional tests will evaluate the characteristics and function of immune cells before and after donor lymphocyte infusion. The total study duration can extend up to several years, with ongoing data collection to understand long-term effects and immune responses.

CONDITIONS

Brief Title

Haploidentical HCT for Severe Aplastic Anemia

Research Team

A

Amr Qudeimat, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here